NHI.no
Annonse
Informasjon

Skrumplever og kronisk leversvikt

Skrumplever, levercirrhose, skyldes i de fleste tilfeller alkoholmisbruk, hepatitt B eller C, eller overvekt. Det er en tilstand som utvikler seg i det stille. Når diagnosen settes, er tilstanden ofte så langtkommen at den er vanskelig å behandle.

Skrumplever eller levercirrhose er ingen uvanlig tilstand.

Sist oppdatert:

7. juni 2023

Vil du vite mer

Dette dokumentet er basert på det profesjonelle dokumentet Levercirrhose og kronisk leversvikt . Referanselisten for dette dokumentet vises nedenfor

  1. Smith A, Baumgartner K, Bositis C. Cirrhosis: diagnosis and management. Am Fam Physician. 2019 Dec 15;100(12):759-770. PubMed
  2. Goldberg E, Chopra S. Cirrhosis in adults: Etiologies, clinical manifestations, and diagnosis. UpToDate, Last updated Jan 23, 2023. UpToDate
  3. Goldberg E, Chopra S. Cirrhosis in adults: Overview of complications, general management, and prognosis. UpToDate, Mar 28, 2023. www.uptodate.com. UpToDate
  4. Paulssen EJ. Når leveren svikter. Indremedisineren. Publisert 24.01.2019. indremedisineren.no
  5. Haukeland JW. Oppfølging av pasienter med levercirrhose. Indremedisineren, 24.01.2019 . indremedisineren.no
  6. Eskesen AN, Bjoro K, Aandahl EM, Line PD, Melum E. Low use of surveillance and early diagnosis of hepatocellular carcinoma in Norway–a population-based cohort study. Cancer Epidemiol. 2014;38(6):741-7. PubMed
  7. Haukeland JW, Lorgen I, Schreiner LT, Frigstad SO, Brandsaeter B, Bjoro K, et al. Incidence rates and causes of cirrhosis in a Norwegian population. Scand J Gastroenterol. 2007;42(12):1501-8. PubMed
  8. Dolman GE, Kennedy PTF. Cirrhosis. BMJ Best Practice, last updated 24 Oct 2019.
  9. National Institute for Health and Care Excellence. Cirrhosis in over 16s: assessment and management. NICE guideline [NG50]. July 2016. Accessed May 28, 2019. www.nice.org.uk
  10. Asrani SK, Kamath PS. Natural history of cirrhosis. Curr Gastroenterol Rep. 2013;15(2):308. PubMed
  11. Bjerring PN, Bojer D. Levercirrose og kronisk leversvigt. Lægehåndbogen. Sist faglig oppdatert 28.11.2022.
  12. Di Martino M, Marin D, Guerrisi A, et al. Intraindividual comparison of gadoxetate disodium-enhanced MR imaging and 64-section multidetector CT in the detection of hepatocellular carcinoma in patients with cirrhosis. Radiology. 2010; 256: 806-16. PubMed
  13. Geng XX, Huang RG, Lin JM, et al. Transient elastography in clinical detection of liver cirrhosis: a systematic review and meta-analysis. Saudi J Gastroenterol. 2016;22(4):294–303.
  14. Kutala BK, Guedj J, Asselah T, Boyer N, Mouri F, Martinot-Peignoux M, et al. Impact of treatment against hepatitis C virus on overall survival of naive patients with advanced liver disease. Antimicrobial agents and chemotherapy. 2015;59(2):803-10. PubMed
  15. Lackner C, Spindelboeck W, Haybaeck J, Douschan P, Rainer F, Terracciano L, et al. Histological parameters and alcohol abstinence determine long-term prognosis in patients with alcoholic liver disease. Journal of hepatology. 2017;66(3):610-8. PubMed
  16. Kamal S, Khan MA, Seth A, et al. Beneficial Effects of Statins on the Rates of Hepatic Fibrosis, Hepatic Decompensation, and Mortality in Chronic Liver Disease: A Systematic Review and Meta-Analysis. Am J Gastroenterol 2017. pmid:28585556 PubMed
  17. Kanwal F, Kramer J, Asch SM, et al. An explicit quality indicator set for measurement of quality of care in patients with cirrhosis. Clin Gastroenterol Hepatol 2010; 8: 709-17. PubMed
  18. Licata G, Tuttolomondo A, Licata A, et al. Clinical trial: high-dose furosemide plus small-volume hypertonic saline solutions vs. repeated paracentesis as treatment of refractory ascites. Aliment Pharmacol Ther 2009; 30: 227-35. PubMed
  19. Helsedirektoratet. Spontan bakteriell peritonitt. Nasjonale retningslinjer. Antibiotika i sykehus. Sist faglig oppdatert: 01. mars 2022. helsedirektoratet.no
  20. Sharma BC, Sharma P, Lunia MK, et al. A randomized, double-blind, controlled trial comparing rifaximin plus lactulose with lactulose alone in treatment of overt hepatic encephalopathy. Am J Gastroenterol. 2013;108:1458-1463. PubMed
  21. Bass NM, Mullen KD, Sanyal A, et al. Rifaximin treatment in hepatic encephalopathy. New Engl J Med 2010; 362: 1071-81. PubMed
  22. Gluud LL, Vilstrup H, Morgan MY. Non‐absorbable disaccharides versus placebo/no intervention and lactulose versus lactitol for the prevention and treatment of hepatic encephalopathy in people with cirrhosis. Cochrane Database of Systematic Reviews 2016, Issue 5. Art. No.: CD003044. The Cochrane Library
  23. Runyon BA; AASLD Practice Guidelines Committee. Management of adult patients with ascites due to cirrhosis: an update. Hepatology 2009; 49: 2087-2107. PubMed
  24. Chavez-Tapia NC, Barrientos-Gutierrez T, Tellez-Avila FI, Soares-Weiser K, Uribe M. Antibiotic prophylaxis for cirrhotic patients with upper gastrointestinal bleeding. Cochrane Database Syst Rev 2010; (9): CD002907. Cochrane (DOI)
  25. Francoz C, Durand F, Kahn JA, Genyk YS, Nadim MK. Hepatorenal Syndrome. Clin J Am Soc Nephrol. 2019 May 7;14(5):774-781. Epub 2019 Apr 17. PMID: 30996046 PubMed
  26. Runyon BA. Hepatorenal syndrome. UpToDate, last updated Dec 13, 2022. UpToDate
  27. Jepsen P, Ott P, Andersen PK, Sørensen HT, Vilstrup H. Risk for hepatocellular carcinoma in patients with alcoholic cirrhosis: a danish nationwide cohort study. Ann Intern Med 2012; 156: 841-7. Annals of Internal Medicine
  28. Martin P, DiMartini A, Feng S, et al. Evaluation for liver transplantation in adults: 2013 practice guideline by the American Association for the Study of Liver Diseases and the American Society of Transplantation. Hepatology. 2014;59(3):1144–1165.
Annonse
Annonse